CTOs on the Move

DeGolers Pharmacies

www.degoler.com

 
DeGolers Pharmacies is a Kansas City, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.degoler.com
  • 7622 State Ave
    Kansas City, KS USA 66112
  • Phone: 913.596.2447

Executives

Name Title Contact Details

Similar Companies

P.E.C.S.

P.E.C.S. is a Canovanas, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

URL Pharma/United Research Laboratories

URL Pharma/United Research Laboratories is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STI Technologies

STI Technologies Limited (STI) is a health-care technology company that provides Canadian patients with greater choice and broader access to the best medications and health care products.

Analgesic Solutions

Analgesic Solutions, LLC., founded in 2006, is a privately held consulting company and Clinical Research Organization. We are a hands-on team of experts across a variety of disciplines who consult on and conduct clinical trials aimed at bringing important new pain treatments to market. With hundreds of projects completed and ongoing collaborations with regulatory authorities, Analgesic Solutions is the premier choice for providing assistance and training to insure successful pain trials. Clients come to us when looking to develop and commercialize better treatments for pain. Our team, with Nathaniel Katz M.D., M.S., serving as our foremost expert, helps our clients bring their pain solutions to commercial reality.

Spectrum Pharmaceuticals

Spectrum`s core mission is to bring pharmaceutical products to patients for unmet medical needs. To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. Spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.